Bionano Genomics (BNGO) Receivables (2017 - 2026)

Bionano Genomics (BNGO) has 10 years of Receivables data on file, last reported at $4.2 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables rose 23.76% year-over-year to $4.2 million; the trailing twelve-month figure through Mar 2026 stood at $4.2 million (up 23.76% YoY), and the FY2025 full-year result was $5.4 million, up 3.67% from the prior year.
• Receivables declined to $4.2 million in Q1 2026, from $5.2 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $10.1 million in Q4 2023 to a low of $3.4 million in Q1 2025.
• A 5-year average of $6.1 million and a median of $6.0 million in 2022 frame the typical range for Receivables.
• Across the five-year window, Receivables jumped 200.05% in 2022 and sank 59.65% in 2025, its largest moves.
• Tracing BNGO's Receivables over 5 years: stood at $7.5 million in 2022, then soared by 35.33% to $10.1 million in 2023, then tumbled by 51.39% to $4.9 million in 2024, then increased by 5.7% to $5.2 million in 2025, then retreated by 20.36% to $4.2 million in 2026.
• Business Quant data shows BNGO's Receivables at $4.2 million in Q1 2026, $5.2 million in Q4 2025, and $4.5 million in Q3 2025.